TargetBeta
OPN1LW
opsin 1, long wave sensitive · also COD5, CBBM, RCP, CBP · Opsin receptors
2 programs in company-led studies act on OPN1LW, from 2 companies: 1 in phase 3. Each with where its target was read from.
Programs
Furthest phase first. A target read by rule is marked rule (2 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.
| Program | Company | Furthest phase | Studies | Also acts on | Read from |
|---|---|---|---|---|---|
| inobrodibrule | CellCentric | phase 3 | 43 running | – | NCIt |
| pocenbrodibrule | Pathos AI | phase 2 | 21 running | – | NCIt |
Conditions their studies are in
- Breast Neoplasms, 1 program
- Hematologic Neoplasms, 1 program
- Multiple Myeloma, 1 program
- Prostatic Neoplasms, 1 program
Primary completions ahead
Each program’s next study to reach its primary completion, by the sponsor’s estimate.
- Mar 31, 2027inobrodib · CellCentric · phase 3 · NCT04068597
- Jun 30, 2028pocenbrodib · Pathos AI · phase 2 · NCT06785636
What this can’t show
- Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
- A target read by rule can be wrong; each program’s page quotes the words it was read from.
- “Acts on” does not say how: an agonist and an antagonist of the same receptor are listed together (avexitide blocks the GLP-1 receptor that semaglutide activates).
- Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.